40 recruiting, 12 active not recruiting, 11 suspended, 10 completed. 94 Phase 1, 29 Phase 2.
Follow Bone Marrow Aspiration: new trials by email Literature Review of Bone Marrow Aspiration trials Research Report on Bone Marrow Aspiration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Asciminib, Biospecimen Collection, Blinatumomab - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 21 | 2027-10-13 | 2026-11-03 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-06 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Venetoclax, Azacitidine - Myeloproliferative Neoplasm | Phase 1 | Not yet recruiting | Roswell Park Cancer Institute | 20 | 2026-12-01 | 2026-10-21 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-12-01 | 2026-10-29 |
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 53 | 2026-11-18 | 2026-08-24 |
| Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Familial Platelet Disorder With Associated Myeloid Malignancy | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 6 | 2026-10-05 | 2026-10-13 |
| ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 38 | 2026-09-30 | 2026-10-05 |
| Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 10 | 2026-09-29 | 2026-10-14 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment Actinium Ac 225 Lintuzumab, Bone Marrow Aspiration, Buccal Swab - Refractory Myelodysplastic Syndrome | Phase 1 | Suspended | National Cancer Institute (NCI) | 18 | 2026-09-03 | 2026-09-09 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia | Phase 1 | Recruiting | National Cancer Institute (NCI) | 47 | 2026-06-09 | 2026-10-23 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 26 | 2026-05-13 | 2026-10-16 |
| Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Bendamustine, Pralatrexate, Bone Marrow Aspiration - Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-04-27 | 2026-05-11 |
Showing 20 of 94. Sign in to see all of them.
Leukemia, Myeloid, Acute (27) · Multiple Myeloma (18) · Myelodysplastic Syndromes (16) · Lymphoma, Large B-Cell, Diffuse (10) · Leukemia, Biphenotypic, Acute (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, Mantle-Cell (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Lymphoma, Follicular (6) · Lymphoma, B-Cell, Marginal Zone (5) · Burkitt Lymphoma (4) · Leukemia, Myelomonocytic, Chronic (4) · Lymphoma, B-Cell (4) · Lymphoma, T-Cell (4) · Neuroblastoma (4)
National Cancer Institute (NCI) (19) · City of Hope Medical Center (18) · Fred Hutchinson Cancer Center (18) · Mayo Clinic (8) · Roswell Park Cancer Institute (4) · University of Washington (4) · Children's Oncology Group (3) · OHSU Knight Cancer Institute (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Abdullah Khan (1) · Alexandra Cristina Senegaglia (1) · Alliance for Clinical Trials in Oncology (1) · Brenda Cooper, MD (1) · Case Comprehensive Cancer Center (1) · Hospital Infantil Universitario Niño Jesús, Madrid, Spain (1)
United States (88) · Canada (3) · Brazil (1) · Spain (1) · Switzerland (1)
Ibrahim Aldoss (3) · Amandeep Salhotra (2) · Elizabeth Krakow (2) · Mark J Roschewski, M.D. (2) · Murali Janakiram (2) · Paul Koller (2) · Phuong Vo (2) · Abdullah M Khan, MBBS, MSc (1) · Alexandra M Stevens (1) · Alexandre Hirayama (1) · Alexandre V. Hirayama, MD (1) · Alice S Mims (1) · Amanda Blackmon (1) · Amit J Sabnis (1) · Anjali S Advani (1)
PMID 22308288, PMID 23354923, PMID 28593306, PMID 31501599, PMID 35175355, PMID 36521030, PMID 36898933, PMID 38683966, PMID 39642902, PMID 40444214, PMID 40535475, PMID 40802906, PMID 42007254, PMID 42013378, PMID 42500906
P30CA033572 (18), UM1CA228823 (6), UM1CA186709 (3), UM1CA186712 (3), P30CA015704 (2), UM1CA186644 (2), K24CA201524 (1), P01CA018029 (1), P01CA078902 (1), P01HL122173 (1), P30CA016058 (1), P30CA069533 (1), P50CA186781 (1), R01CA262613 (1), R44CA192601 (1)